Bruzzese Antonella, Vigna Ernesto, Terzi Dario, Greco Sonia, Martino Enrica Antonia, Vangeli Valeria, Mendicino Francesco, Lucia Eugenio, Olivito Virginia, Labanca Caterina, Morelli Rosellina, Neri Antonino, Morabito Fortunato, Zinno Francesco, Mastroianni Antonio, Gentile Massimo
Hematology Unit, Azienda Ospedaliera Annunziata, 87100 Cosenza, Italy.
Immunohaematology Section, Annunziata Hospital, 87100 Cosenza, Italy.
Hematol Rep. 2023 Jul 20;15(3):448-453. doi: 10.3390/hematolrep15030046.
Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening, rare acute thrombotic microangiopathy (TMA), caused by a severe ADAMTS13 deficiency. As the COVID-19 pandemic rapidly spread around the globe, much data about the pathogenicity of this virus were published. Soon after the detection of the first cases of COVID-19, it was clear that there was a wide range of COVID coagulopathy manifestations, such as deep venous thrombosis, pulmonary thromboembolism, and thrombotic microangiopathies. In the literature, little data have been reported about the association between TTP and COVID-19, and the treatment of COVID-19-associated TTP is still under debate. Here we present the case of a 46-year-old woman who developed a COVID-associated TTP, successfully treated with plasma exchange (PEX), steroids, and caplacizumab.
血栓性血小板减少性紫癜（TTP）是一种由严重的ADAMTS13缺乏引起的、潜在危及生命的罕见急性血栓性微血管病（TMA）。随着新冠疫情在全球迅速蔓延，大量关于该病毒致病性的数据得以公布。在检测到首例新冠病例后不久，很明显出现了广泛的新冠凝血病表现，如深静脉血栓形成、肺血栓栓塞和血栓性微血管病。在文献中，关于TTP与新冠之间关联的报道较少，且新冠相关TTP的治疗仍存在争议。在此，我们报告一例46岁女性发生新冠相关TTP的病例，该患者通过血浆置换（PEX）、类固醇和卡泊单抗成功治愈。
